Healthcare Equipment and Supplies
Company Overview of EndoGastric Solutions, Inc.
EndoGastric Solutions, Inc., a medical device company, develops, markets, and sells natural orifice surgical products and procedures to advance the treatment of gastrointestinal diseases. It offers EsophyX, a technology that enables transoral reconstructive surgery; SerosaFuse Fasteners, a non-resorbable polypropylene material product that have equivalent web strength to a 3.0 suture; trainer-led courses for surgeons; and consultative, support, pre-authorization, internal appeal, and external medical review services. The company was formerly known as EsophyX, Inc. and changed its name to EndoGastric Solutions, Inc. in 2005. EndoGastric Solutions, Inc. was founded in 2002 and is headquartered...
1900 O'Farrell Street
San Mateo, CA 94403
Founded in 2002
Key Executives for EndoGastric Solutions, Inc.
Chief Executive Officer, President and Director
Director of Finance and Controller
Senior Director of US Sales
Compensation as of Fiscal Year 2015.
EndoGastric Solutions, Inc. Key Developments
EndoGastric Solutions Secures $50 Million in Financing
Dec 1 15
EndoGastric Solutions announced that it has secured additional new financing of up to $50.0 million, led by CRG (formerly Capital Royalty L.P.) and existing EGS investors including Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, Foundation Medical Partners, and Radius Ventures. EGS plans to use proceeds from the financing to begin broad-scale commercialization, as well as making further R&D investments in next generation products used in their TIF procedure.
EndoGastric Solutions Names Michael K. Burke as Chief Financial Officer
Nov 17 15
EndoGastric Solutions announced that industry veteran Michael K. Burke has been named Chief Financial Officer. Mr. Burke is a seasoned financial executive with over 30 years of experience. Mr. Burke has held several leadership positions in finance. He most recently served as Senior Vice President and Chief Financial Officer of Landauer, Inc. Prior to this, Mr. Burke was the Senior Vice President and Chief Financial Officer of Albany International Corp. and as the Executive Vice President and Chief Financial Officer of Intermagnetics General Corporation.
Endogastric Announces One-Year Clinical Data from the RESPECT Study
Oct 19 15
EndoGastric Solutions, Inc. announced updated one-year clinical data from the RESPECT (Randomized EsophyX® vs. Sham/Placebo Controlled Trial) study, the first-ever randomized, blinded, sham- and placebo-controlled study of the company's Transoral Incisionless Fundoplication (TIF®) procedure. The RESPECT study, along with a second separate study of health economic data comparing reflux treatment methods including the TIF procedure, will be presented at the American College of Gastroenterology (ACG) 2015 Annual Scientific Meeting, October 16- 21, 2015 in Honolulu, Hawaii. Eighty-seven patients were randomly assigned to the group that underwent the TIF procedure and then received an ongoing treatment of placebo medication. After more than 12 months, 72% reported elimination of troublesome regurgitation per Montreal consensus criteria. The study also found that the mean DeMeester Score decreased from 33.6 to 23.9 at 6 months and to 24.7 at > 12 months post-TIF (p < 0.05).
Similar Private Companies By Industry
Recent Private Companies Transactions
May 12, 2015
April 10, 2015